

Effect of upadacitinib on cutaneous transcriptomic and systemic proteomic dysregulation in patients with moderate-to-severe atopic dermatitis
In this medfyle
Changes in the AD transcriptome may help evaluate targeted therapies. This biomarker analysis from Heads Up shows upadacitinib improved the transcriptome to a greater extent than dupilumab.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Dr. Emma Guttman-Yassky
Icahn School of Medicine at Mount Sinai
New York, United States
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.